产业经济周观点：2023年医药研发概览

Group 1 - The report highlights that all six sub-sectors of the pharmaceutical index recorded positive returns, indicating strong performance in the industry [1] - According to the "2024 China Pharmaceutical R&D Blue Book" published by Yaozhi Network, the Chinese pharmaceutical industry demonstrated vitality in 2023 across policy, market, research and development, and investment [1][10] - The report notes that the market size is expanding, with sales growth in public medical institutions and retail pharmacies, while the oncology drug market shows stable growth, and the cardiovascular and metabolic sectors are experiencing contraction [1][10] Group 2 - In terms of research and development, the number of clinical applications for innovative Class 1 drugs reached a historical high, with oncology and hematology being hot areas of focus [10][11] - The report indicates that Chinese pharmaceutical companies have made breakthroughs in international markets, with license-out transactions surpassing license-in transactions, reflecting the growing international influence of Chinese drug companies [10][11] - The investment landscape in 2023 saw a decline in both the number and amount of financing events, indicating a more cautious investment attitude in the pharmaceutical sector [10][11] Group 3 - The report tracks the recent inclusion of 24 non-reimbursed drugs into centralized procurement, which may lead to comprehensive price reductions in self-funded medical care [28][29] - The 2024 adjustment of the national medical insurance drug list added 91 new drugs, expected to reduce patient costs by over 50 billion yuan, with a focus on innovative drugs and improved coverage for critical areas [32][33] - The report emphasizes that the successful negotiation rate for new drugs exceeded 90%, highlighting the government's commitment to enhancing the accessibility of innovative treatments [32][33]